# Xilis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xilis

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.xilis.net
- Total disclosed funding: $90M
- Latest round: Series A (Jun 1, 2022)
- Investors on record: 14

## About

Xilis, Inc. is a US-based biotechnology company that develops advanced diagnostic solutions using proprietary microfluidic technology to analyze patient samples for precision oncology.Founded in 2019 and headquartered in Durham, US, Xilis, Inc. focuses on biotechnology and has undergone strategic developments aligning with advancements in precision medicine. The company was founded by Thomas Duke and Xiling Shen. The firm completed its Series A funding round on June 1, 2022, raising a total of USD 16.51 mn, led by FPV Ventures with numerous other notable investors participating. The total amount raised by Xilis, Inc. amounts to USD 16.51 mn, resulting in a current company valuation of USD 288.39 mn.Xilis specializes in advanced diagnostic solutions that leverage proprietary microfluidic technology to analyze patient samples at a cellular level. Their core product offerings include tools for precision oncology, which enable healthcare providers to personalize treatment by understanding tumor biology and response to therapies. Targeting hospitals, cancer treatment centers, and research institutions across North America and parts of Europe, Xilis aims to enhance personalized medicine in regions with critical oncology care needs.Xilis generates revenue primarily through partnerships with healthcare providers and institutions, focusing on B2B transactions. They offer subscription-based access to their diagnostic tools alongside one-time service fees for comprehensive analyses. Clients utilize Xilis' flagship products for treatment planning and monitoring in oncology settings, with pricing structures reflecting the value of insights provided.Xilis, Inc. plans to utilize the USD 16.51 mn raised in its recent Series A funding to propel future growth initiatives. The company is working on launching new diagnostic products aimed at enhancing precision oncology capabilities. Moreover, Xilis aims to expand its market reach into additional regions in Europe and Asia by 2024, focusing on areas with a high demand for personalized cancer treatment solutions. The funding will facilitate the acceleration of product development and market entry strategies.

## Funding rounds

- Series A, Jun 1, 2022, $17M — EQT Life Sciences, Alexandria Venture Investments, Two Sigma Investments, GV, Felicis Ventures, Pear VC, Duke Angel Network, Mubadala Capital, Catalio Capital Management, Alix Ventures, FPV Ventures
- Series A, Jun 1, 2020, $70M — EQT Life Sciences, Two Sigma Investments, GV, Felicis Ventures, Pear VC, Duke Angel Network, KdT Ventures, Mubadala Capital, Catalio Capital Management, Alix Ventures
- Seed, Dec 10, 2019, $3M — Felicis Ventures, Pear VC, Liquid 2 Ventures, 8VC

## Investors

- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Seed, Series A
- Pear VC (https://capitalatlas.ai/funds/pear-vc) — Seed, Series A
- Liquid 2 Ventures (https://capitalatlas.ai/funds/liquid-2-ventures) — Seed
- 8VC (https://capitalatlas.ai/funds/8vc) — Seed
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Two Sigma Investments (https://capitalatlas.ai/funds/two-sigma-investments) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A
- Duke Angel Network — Series A
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Series A
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series A
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A
- Alix Ventures (https://capitalatlas.ai/funds/alix-ventures) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- FPV Ventures (https://capitalatlas.ai/funds/fpv-ventures) — Series A